Special “Protein Partners” May Be Effective Against the Progression of Human Pancreatic Cancer

The transcription factor Prdm16 functions as a potent suppressor of transforming growth factor beta (TGF-β) signaling, and its inactivation is thought to promote the progression of pancreatic ductal adenocarcinoma. Recently, in an article published in the Cell Biology titled "Antagonism between Prdm16 and Smad4 specifies the trajectory and progression of pancreatic cancer", scientists from Virginia Commonwealth University and other institutions uncovered the previously undiscovered special association between two groups of special proteins. The tandem operation of histones prevents the growth of pancreatic cancer, and the findings may provide scientists with important information to help develop new treatments for pancreatic cancer.

Pancreatic ductal adenocarcinoma accounts for the vast majority of all pancreatic tumors, and it is also the fourth leading cause of cancer-related death worldwide. Most patients are diagnosed at an advanced stage of the disease, when the patient is no longer able to undergo surgery and there is no effective treatment. In this study, the researchers found that simultaneous activation of two gene-regulatory proteins called Prdm16 and Smad4 may be associated with stalled pancreatic cancer progression. "Our study reveals an uncharacterized interaction between the two proteins that appears to determine the growth trajectory of pancreatic cancer and may ultimately help scientists develop innovative treatments for this deadly disease," said researcher Atfi.

Loss of Smad4 was previously found to be associated with cancer growth in pancreatic ductal adenocarcinoma cells, while Prdm16 controls a variety of essential cellular processes, including tissue and organ building, first observed in leukemia and previously findings suggest that it may act as a tumor suppressor, but it has not been studied in pancreatic cancer. Now researchers show that when both Prdm16 and Smad4 are inactivated, pancreatic cancer tumors begin to grow uncontrollably and form metastatic lesions in the lungs; however, they also found that when Smad4 alone is inactivated, Prdm16 can be overexpressed and promote cancer growth.

When the researchers analyzed the properties of cells in which both proteins are activated (Prdm16 is located downstream of the same genetic information pathway as Smad4), the researchers found that Prdm16 successfully suppressed tumor progression and metastasis of pancreatic cancer cells, which may suggests that both play important and combinatorial roles in helping to defend against cancer cell progression. We can imagine Smad4 as a movie director, which tells Prdm16 how to fulfill the role of cancer defense guard. Without Smad4 as a director, Prdm16 will start to play the role of cancer support; This mechanism can coordinate the anti-tumor effect of Prdm16, and at the same time, it can further elucidate the novel molecular causes of pancreatic carcinogenesis.

Later, researchers must conduct more in-depth studies to determine whether Prdm16 can cause some anti-tumor activity at an early stage, and whether this process occurs through direct effects on cancer cell growth or reprogramming of the tumor microenvironment; Thus, a better understanding of the mechanism by which Smad4 and Prdm16 interact may help identify additional genetic players that can be targeted by cancer therapies. The results of the study may help researchers better understand and uncover the cellular patterns of pancreatic carcinogenesis.

Taken together, these findings uncover an unprecedented antagonism between the tumor suppressor Smad4 and Prdm16, which functions to limit the progression and metastasis of pancreatic ductal adenocarcinoma.

Article source: https://article-realm.com/article/Sports-Recreation/41558-Special-Protein-Partners-May-Be-Effective-Against-the-Progression-of-Human-Pancreatic-Cancer.html